Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 72.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 15.00 (23.077%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 72.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Nov 2014 07:00

RNS Number : 0309W
Biome Technologies PLC
04 November 2014
 



04 November 2014

 

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the nine months ended 30 September 2014.

 

Total Group revenues achieved for the third quarter were £0.5m (Q3 2013: £0.6m) taking Group revenues for the nine months to 30 September 2014 to £2.8m, 85% ahead of the same period in 2013 (2013: £1.5m). The Group's cash position as at 30 September 2014 was £2.8m (30 June 2014: £3.1m).

Bioplastics Division

Revenues for the Bioplastics division in Q3 were £0.1m (Q3 2013: £0.4m), down substantially on the previous two quarters. Offtake reduced to the single-serve coffee market in the USA as the main customer responded to technical challenges in the market place and ran down stocks ahead of re-launches. The Board believes that these effects are temporary and that revenue growth will resume in the near future.

Further progress was made in the development of the pipeline of new bioplastic polymers with technical and customer trials continuing in both the food service and paper-board coating sectors. The business launched a new product in September, formulated to improve both speed and performance in 3D printing applications, whilst retaining impeccable environmental credentials. This is the division's first foray into this emerging sector and initial response from end-use customers is encouraging.

Earlier in the year, the division announced the successful completion of a feasibility study undertaken in conjunction with the University of Warwick and supported by Innovate UK (formerly the Technology Strategy Board). This study examined the feasibility of producing a bacterially derived lignin-based alternative to the oil-based chemicals used in the manufacture of bioplastics. The Board is exploring options for further scale-up of this technology and is awaiting the result of a further grant application to Innovate UK. The result of this application is expected in the near future.

 

Stanelco RF Technologies Division

Revenues for the RF division remained firm at £0.4m (Q3 2013: £0.2m). Demand from the optical fibre furnace market in Asia continues to underpin revenues whilst products for a broader portfolio of market applications are progressing well. The unit's order-book into 2015 is robust and recruitment has been recently completed to extend both capacity and capability.

 

Outlook

The Board remains confident of meeting market expectations for the year.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

Daniel Stewart & Company plc

Paul Shackleton (Nominated Adviser)

Mark Treharne (Broker)

www.danielstewart.co.uk

Tel: +44 (0) 20 7776 6550

Allenby Capital

Chris Crawford/Kelly Gardiner

www.allenbycapital.com

Tel: +44 (0) 20 3002 2070

FTI Consulting

Oliver Winters

www.fticonsulting.com

Tel: +44 (0) 20 3727 1535

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKNDBABDDPDK
Date   Source Headline
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.